PROCEPT BioRobotics (PRCT) vs. Its Competitors Head-To-Head Comparison

PROCEPT BioRobotics (NASDAQ:PRCT) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its competitors? We will compare PROCEPT BioRobotics to related companies based on the strength of its dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Volatility & Risk

PROCEPT BioRobotics has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics’ competitors have a beta of 2.52, indicating that their average stock price is 152% more volatile than the S&P 500.

Profitability

This table compares PROCEPT BioRobotics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-32.53%	-30.62%	-22.10%
PROCEPT BioRobotics Competitors	-278.24%	-150.08%	-21.87%

Institutional & Insider Ownership

89.5% of PROCEPT BioRobotics shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 4.0% of PROCEPT BioRobotics shares are held by insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for PROCEPT BioRobotics and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2	9	2	3	2.38
PROCEPT BioRobotics Competitors	4274	10549	18323	829	2.46

PROCEPT BioRobotics currently has a consensus target price of $25.25, indicating a potential upside of 22.45%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.34%. Given PROCEPT BioRobotics’ higher possible upside, research analysts plainly believe PROCEPT BioRobotics is more favorable than its competitors.

Valuation and Earnings

This table compares PROCEPT BioRobotics and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05 million	-$95.57 million	-10.21
PROCEPT BioRobotics Competitors	$1.88 billion	$139.14 million	9.47

PROCEPT BioRobotics’ competitors have higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

PROCEPT BioRobotics competitors beat PROCEPT BioRobotics on 8 of the 13 factors compared.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.